Development of Serous Ovarian Cancer is Associated with the Expression of Homologous Recombination Pathway Proteins

Pathology and Oncology Research

Volumn 20, Issue 4, 2014, Pages 931-938

  Ye, Qingqing ^a   Chen, Li ^b   Yin, Xiaolu ^a   Liu, Yuan Jie Charles ^a   Ji, Qunsheng ^a   Zhao, Enfeng ^c  

^a ASTRAZENECA   (United Kingdom)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Hainan Branch of General Hospital of PLA   (China)

Author keywords

Ataxia telangiectasia mutated (ATM); ATM Rad3 related (ATR); Breast cancer susceptibility gene 1 (BRCA1); Homologous recombination (HR); Immunohistochemistry (IHC); Mediator of DNA damage checkpoint protein 1 (MDC1); Meiotic recombination 11 (Mre11); Serous ovarian cancer (SOC)

Indexed keywords

ATM PROTEIN; ATM PROTEIN, HUMAN; ATR PROTEIN, HUMAN; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; DNA BINDING PROTEIN; MDC1 PROTEIN, HUMAN; MRE11A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADULT; AGED; CANCER GRADING; CANCER STAGING; CYSTADENOCARCINOMA; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HOMOLOGOUS RECOMBINATION; HUMAN; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ATAXIA TELANGIECTASIA MUTATED PROTEINS; BRCA1 PROTEIN; CYSTADENOCARCINOMA, SEROUS; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HOMOLOGOUS RECOMBINATION; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84939897966     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-014-9776-8     Document Type: Article

References (35)

1. Van Gent DC, Hoeijmakers JHJ, Kanaar R (2001) Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2(3):196–206
2. Watson JD (1970) Molecular biology of the gene. Molecular biology of the gene (2nd edn)
3. Haber JE (2000) Partners and pathways: repairing a double-strand break. Trends Genet 16(6):259–264
4. Shrivastav M, De Haro LP, Nickoloff JA (2007) Regulation of DNA double-strand break repair pathway choice. Cell Res 18(1):134–147
5. Carson CT, Schwartz RA, Stracker TH, Lilley CE, Lee DV, Weitzman MD (2003) The Mre11 complex is required for ATM activation and the G2/M checkpoint. The EMBO J 22(24):6610–6620
6. Goldberg M, Stucki M, Falck J, D’Amours D, Rahman D, Pappin D, Bartek J, Jackson SP (2003) MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 421(6926):952–956
7. Stewart GS, Wang B, Bignell CR, Taylor AMR, Elledge SJ (2003) MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421(6926):961–966
8. Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15(17):2177–2196
9. Cortez D, Wang Y, Qin J, Elledge SJ (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286(5442):1162–1166
10. Helleday T Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31 (6):955–960
11. Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432(7015):316–323
12. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O’Connor MJ, Tutt AN, Zdzienicka MZ (2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 66(16):8109
13. Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY, Yu JC (2007) Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex. Cancer Epidemiol Biomark Prev 16(10):2024–2032
14. Bartkova ZH J (2007) DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26(53):7414–7422
15. Giannini G, Rinaldi C, Ristori E, Ambrosini MI, Cerignoli F, Viel A, Bidoli E, Berni S, D’Amati G, Scambia G (2004) Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene 23(15):2640–2647
16. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, Ottini L, Crescenzi M, Martinotti S, Bignami M (2002) Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 3(3):248–254
17. Liu ZK, Zhu SC, Wang YX (2007) Expression of DNA damage checkpoint mediator 1 and p53-binding protein 1 in human esophageal cancer cell lines TE-1, TE-13, and Eca109]. Nan fang yi ke da xue xue bao=. J of South Med Univ 27(9):1314
18. Shiloh Y, Kastan MB (2001) ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res 83:209–254
19. Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA (2002) Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 94(3):205–215
20. Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, Muhr D, Wayne TL, Chu G, Davis RW (2003) Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res 63(12):3325
21. Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B (2006) Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 6(1):230
22. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE (2002) Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94(1):61–67
23. Welcsh PL, King MC (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10(7):705–713
24. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J clin 56(2):106–130
25. Auranen A, Song H, Waterfall C, DiCioccio RA, Kuschel B, Kjaer SK, Hogdall E, Hogdall C, Stratton J, Whittemore AS (2005) Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer 117(4):611–618
26. Powell SN, Willers H, Xia F (2002) BRCA2 Keeps Rad51 in Line: High-Fidelity Homologous Recombination Prevents Breast and Ovarian Cancer? Mol Cell 10(6):1262–1263
27. Heikkinen K, Mansikka V, Karppinen SM, Rapakko K, Winqvist R (2005) Mutation analysis of the ATR gene in breast and ovarian cancer families. Breast Cancer Res 7(4):R495–501
28. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16(7):2417–2425
29. Brown PO, Palmer C (2009) The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med 6(7):e1000114
30. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ (2007) SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub (07–6215)
31. Esteban Cardeñosa E, Bolufer Gilabert P, de Juan Jiménez I, Palanca Suela S, Barragán González E, González Anguix V, Lerma Alejos E, Chirivella González I, Segura Huerta Á, Guillén Ponce C, Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence. Familial cancer 9 (3):291–295
32. Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84(1):16–28
33. Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, Abeliovich D, Peretz T (2007) Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 44(7):467–471
34. Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365
35. W-b L, Ao L, Z-h C, Z-y Z, Y-h Z, X-y Y, Y-l X, Cao J, J-y L (2011) Molecular analysis of DNA repair gene methylation and protein expression during chemical-induced rat lung carcinogenesis. Biochem Biophys Res Commun 408(4):595–601